HITS Information

HITS is revolutionizing drug discovery by moving beyond simple predictive tools into the era of "Lab Automation." We are fundamentally shifting the Bio-R&D paradigm by empowering AI agents to independently design and execute complex research procedures, delivering new therapies to patients with untreatable conditions faster than ever before. Our ecosystem is driven by HyperLab, which leverages the national flagship model 'K-Fold' to screen tens of trillions of compounds with world-class accuracy. Complementing this is OmicsHorizon, a specialized biological AI agent that understands researcher intent to autonomously design workflows—outperforming general-purpose models from global big tech in solving professional biomedical problems. As a lead agency for the Ministry of Science and ICT’s next-generation Bio-AI project, HITS is securing South Korea’s technical sovereignty. Our technology has been verified under the rigorous "AI Special Technology Listing Track," proving our core IP is proprietary and free from "AI washing" or "wrapper" vulnerabilities as we execute our roadmap toward a successful IPO. With a foundation in KAIST expertise and ongoing joint commercialization with Fortune 500 leaders, HITS is setting the new global standard for AI-led research. Join us in our mission to contribute to human health through the next generation of autonomous biotech.